Abstract
Estimating the true magnitude of the United States (US) SARS-CoV-2 epidemic is crucial for understanding disease dynamics and, ultimately, for determining the effectiveness of interventions intended to interrupt transmission. We developed a Bayesian evidence synthesis model that explicitly accounts for reporting delays and secular variation in case ascertainment to generate estimates of incident COVID-19 infections on the basis of reported cases and deaths. We estimate time trends in COVID-19 epidemiology for every US state and county, from the first reported case (January 13, 2020) through January 1, 2021. Across counties, we estimate considerable variability in the level and pattern of incidence, producing major differences in the estimated proportion of the population infected by the end of 2020. Our estimates of COVID-19 deaths are consistent with independent estimates of excess mortality, and our estimates of cumulative incidence of infection are consistent with seroprevalence estimates from available antibody testing studies.
Competing Interest Statement
DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant from Pfizer on an unrelated topic. VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors have declared that no competing interest exist.
Funding Statement
KG reports grant from National Institutes of Health T32 GM007205 and Fogarty International Center D43 TW010540 VEP reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093 DMW reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093 JLW reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093 TC reports grants from National Institute of Allergy and Infectious Diseases R01 AI112438 NAM reports grants from National Institute of Allergy and Infectious Diseases R01 AI146555-01A1 JAS reports funding from the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-02) and the National Institute on Drug Abuse (3R37DA01561217S1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵& These authors share senior authorship
Data Availability
All data used in the main analysis are available from The Covid Tracking Project and Johns Hopkins CSSE.
https://www.mass.gov/info-details/covid-19-response-reporting
